Baseline characteristics of all included women (N=2151) having a primary surgical procedure for UI in Denmark, 1996–2010
| Exposed* n=496 | Unexposed† n=1655 | |
|---|---|---|
| Mean age (±SD), years (at time of first UI surgery) | 60.2 (±13.2) | 54.2 (±12.4) |
| Age groups, n (%) | ||
| 18–39 | 30 (6.1) | 182 (11.0) |
| 40–59 | 196 (39.5) | 911 (55.1) |
| 60− | 270 (54.4) | 562 (33.9) |
| Procedures, n (%) | ||
| rpMUS | 140 (28.2) | 535 (32.3) |
| toMUS | 222 (44.8) | 750 (45.3) |
| Bulking | 110 (22.2) | 250 (15.1) |
| Others | 24 (4.8) | 120 (7.3) |
| Concomitant prolapse surgery, n (%) | 12 (2.4) | 66 (4.0) |
| Antibiotics before surgery, n (%)‡ | ||
| Sulfamethizol—J01EB02 | 299 (60.3) | – |
| Pivmecillinam—J01CA08 | 288 (58.1) | – |
| Nitrofurantoin—J01XE01 | 65 (13.1) | – |
| Trimethoprim—J01EA01 | 45 (9.1) | – |
| Mecillinam—J01CA11 | 0 (0) | – |
| Oestrogen users, n (%)§ | ||
| No | 211 (42.5) | 997 (60.2) |
| Yes | 285 (57.5) | 658 (39.8) |
| Comorbidity (CCI), n (%) | ||
| 0 | 298 (60.1) | 1214 (73.4) |
| 1–2 | 139 (28.0) | 381 (23.0) |
| 3+ | 59 (11.9) | 60 (3.6) |
| Educational level, n (%)¶ | ||
| Basic | 229 (47.4) | 688 (42.3) |
| Secondary | 170 (35.2) | 600 (36.8) |
| Higher | 84 (17.4) | 340 (20.9) |
| Annual income, n (%) | ||
| Low (1st quartile) | 152 (30.7) | 385 (23.3) |
| Middle (2nd–3rd quartile) | 252 (50.8) | 825 (49.9) |
| High (4th quartile) | 92 (18.5) | 445 (26.9) |
| Year of surgery n (%) | ||
| 1996–2006 | 106 (21.4) | 353 (21.3) |
| 2007–2008 | 186 (37.5) | 605 (36.6) |
| 2009–2010 | 204 (41.1) | 697 (42.1) |
*Exposed women had redeemed one or more prescriptions of antibiotics within 365 days preceding the date of surgery. †Unexposed women had not redeemed prescriptions of antibiotics within 365 days preceding the date of surgery.
‡Does not sum up to 100%. Some women redeemed more than one type of the drugs during the time period.
§Women with at least one redeemed prescription of oestrogen within 365 days preceding the date of surgery.
¶Unknown highest attained educational level: 40 women.
CCI, Charlson comorbidity index; rpMUS, retropubic mid-urethral sling, toMUS, trans-obturator mid-urethral sling.